A temporal role of type I interferon signaling in CD8 + T cell maturation during acute West Nile virus infection

PLoS Pathogens

Volumn 7, Issue 12, 2011, Pages

  Pinto, Amelia K ^a   Daffis, Stephane ^a,b   Brien, James D ^a   Gainey, Maria D ^a   Yokoyama, Wayne M ^a   Sheehan, Kathleen C F ^a   Murphy, Kenneth M ^a   Schreiber, Robert D ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8ALPHA ANTIGEN; INTERFERON; NEUTRALIZING ANTIBODY; ALPHA BETA INTERFERON RECEPTOR; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CD8 ANTIGEN; CD8 ANTIGEN, ALPHA CHAIN; REPRESSOR PROTEIN; SNFT PROTEIN, MOUSE;

ACUTE WEST NILE VIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RESPONSE; DENDRITIC CELL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; VIRUS INFECTION; VIRUS LOAD; WEST NILE FLAVIVIRUS; ACUTE DISEASE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; MOUSE MUTANT; TIME; WEST NILE FEVER;

MUS; WEST NILE VIRUS;

ACUTE DISEASE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD8; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; INTERFERON TYPE I; MICE; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84855284258     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002407     Document Type: Article

References (67)

1. Isaacs A, Lindenmann J, (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147: 258-267.
2. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD, (1998) How cells respond to interferons. Annu Rev Biochem 67: 227-264.
3. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
4. Colonna M, Trinchieri G, Liu YJ, (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226.
5. Samuel MA, Diamond MS, (2006) Pathogenesis of West Nile virus infection: A balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 80: 9349-9360.
6. Daffis S, Suthar MS, Szretter KJ, Gale M Jr, Diamond MS, (2009) Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog 5: e1000607.
7. Mackenzie JS, Gubler DJ, Petersen LR, (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S98-109.
8. Samuel MA, Diamond MS, (2005) Type I IFN protects against lethal West Nile Virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 79: 13350-13361.
9. Le Bon A, Tough DF, (2002) Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14: 432-436.
10. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Fernandez de Sanmamed M, Le Bon A, et al. (2011) Direct Effects of type I IFNs on cells of the immune system. Clin Cancer Res 17: 2619-2627.
11. Purtha WE, Chachu KA, Virgin HW, Diamond MS, (2008) Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J Virol 82: 10964-10974.
12. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, et al. (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
13. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, et al. (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176: 2074-2078.
14. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
15. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL, (2010) Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity 33: 96-105.
16. Quigley M, Huang X, Yang Y, (2008) STAT1 signaling in CD8 T cells is required for their clonal expansion and memory formation following viral infection in vivo. J Immunol 180: 2158-2164.
17. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, et al. (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4: 1009-1015.
18. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, et al. (2008) Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322: 1097-1100.
19. Frenz T, Waibler Z, Hofmann J, Hamdorf M, Lantermann M, et al. (2010) Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. Eur J Immunol 40: 2769-2777.
20. Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, et al. (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28: 675-686.
21. Detje CN, Meyer T, Schmidt H, Kreuz D, Rose JK, et al. (2009) Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol 182: 2297-2304.
22. Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, et al. (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176: 4682-4689.
23. Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, et al. (2006) Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 26: 804-819.
24. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, et al. (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684.
25. Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, et al. (2006) PKR and RNAse L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 80: 7009-7019.
26. Delhaye S, Paul S, Blakqori G, Minet M, Weber F, et al. (2006) Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci USA 103: 7835-7840.
27. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K, (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637-650.
28. Coro ES, Chang WL, Baumgarth N, (2006) Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 176: 4343-4351.
29. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M, (2003) B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77: 2578-2586.
30. Diamond MS, Sitati E, Friend L, Shrestha B, Higgs S, et al. (2003) A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 198: 1853-1862.
31. Shrestha B, Diamond MS, (2004) The role of CD8+ T cells in the control of West Nile virus infection. J Virol 78: 8312-8321.
32. Wang Y, Lobigs M, Lee E, Mullbacher A, (2003) CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 77: 13323-13334.
33. Purtha WE, Myers N, Mitaksov V, Sitati E, Connolly J, et al. (2007) Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol 37: 1845-1854.
34. Brien JD, Uhrlaub JL, Nikolich-Zugich J, (2007) Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol 37: 1855-1863.
35. Beasley DW, Li L, Suderman MT, Barrett AD, (2002) Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 296: 17-23.
36. Keller BC, Fredericksen BL, Samuel MA, Mock RE, Mason PW, et al. (2006) Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 80: 9424-9434.
37. Dikopoulos N, Bertoletti A, Kroger A, Hauser H, Schirmbeck R, et al. (2005) Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol 174: 99-109.
38. Liu XS, Xu Y, Hardy L, Khammanivong V, Zhao W, et al. (2003) IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol 171: 4765-4772.
39. Lanteri MC, O'Brien KM, Purtha WE, Cameron MJ, Lund JM, et al. (2009) Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest 119: 3266-3277.
40. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, et al. (2006) IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 36: 2046-2060.
41. Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, et al. (2010) Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion. J Immunol 185: 6013-6022.
42. Edelson BT, Kc W, Juang R, Kohyama M, Benoit LA, et al. (2010) Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J Exp Med 207: 823-836.
43. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, et al. (2006) Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203: 2461-2472.
44. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, et al. (2006) Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12: 1301-1309.
45. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R, (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911-4927.
46. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188: 2205-2213.
47. Daffis S, Lazear HM, Liu WJ, Audsley M, Engle M, et al. (2011) The naturally attenuated Kunjin strain of West Nile virus shows enhanced sensitivity to the host type I interferon response. J Virol 85: 5664-5668.
48. Zietara N, Lyszkiewicz M, Gekara N, Puchalka J, Dos Santos VA, et al. (2009) Absence of IFN-beta impairs antigen presentation capacity of splenic dendritic cells via down-regulation of heat shock protein 70. J Immunol 183: 1099-1109.
49. Huber JP, Farrar JD, (2011) Regulation of effector and memory T-cell functions by type I interferon. Immunology 132: 466-474.
50. Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K, (2006) Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 177: 1746-1754.
51. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U, (2006) Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108: 3253-3261.
52. Cousens LP, Peterson R, Hsu S, Dorner A, Altman JD, et al. (1999) Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J Exp Med 189: 1315-1328.
53. Harrington LE, Galvan M, Baum LG, Altman JD, Ahmed R, (2000) Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med 191: 1241-1246.
54. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, et al. (2003) Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4: 1191-1198.
55. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, et al. (2008) Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 205: 625-640.
56. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
57. Heath WR, Carbone FR, (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19: 47-64.
58. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
59. Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF, (2009) Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol 182: 2786-2794.
60. Tough DF, (2004) Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45: 257-264.
61. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, et al. (1996) High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184: 741-746.
62. Brien JD, Uhrlaub JL, Hirsch A, Wiley CA, Nikolich-Zugich J, (2009) Key role of T cell defects in age-related vulnerability to West Nile virus. J Exp Med 206: 2735-2745.
63. Ebel GD, Dupuis AP III, Ngo K, Nicholas D, Kauffman E, et al. (2001) Partial genetic characterization of West Nile Virus strains, New York State, 2000. Emerg Inf Dis 7: 650-653.
64. Mehlhop E, Diamond MS, (2006) Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203: 1371-1381.
65. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, et al. (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201: 95-104.
66. Byers AM, Kemball CC, Moser JM, Lukacher AE, (2003) Cutting edge: rapid in vivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells. J Immunol 171: 17-21.
67. Jellison ER, Kim SK, Welsh RM, (2005) Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 174: 614-618.